Bram Ramaekers

Summary

Publications

  1. Ramaekers B, Janssen Boyne J, Gorgels A, Vrijhoef H. Adherence among telemonitored patients with heart failure to pharmacological and nonpharmacological recommendations. Telemed J E Health. 2009;15:517-24 pubmed publisher
    ..Longer-term results will enable solid conclusions to be reached concerning the relation between telemonitoring and patients' adherence. ..
  2. Lambin P, Ramaekers B, van Mastrigt G, Van Den Ende P, De Jong J, De Ruysscher D, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev. 2009;:CD006158 pubmed publisher
    ..Nevertheless, based on these findings EPO should not be administered as an addition to RT outside the experimental setting for patients with head and neck cancer. ..
  3. Grutters J, Sculpher M, Briggs A, Severens J, Candel M, Stahl J, et al. Acknowledging patient heterogeneity in economic evaluation : a systematic literature review. Pharmacoeconomics. 2013;31:111-23 pubmed publisher
    ..The improved acknowledgement of patient heterogeneity in future economic evaluations may well improve the efficiency of healthcare. ..
  4. Ramaekers B, Riemsma R, Tomini F, van Asselt T, Deshpande S, Duffy S, et al. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. Pharmacoeconomics. 2017;35:191-202 pubmed publisher
    ..Moreover, in March 2016, the AC produced the final guidance, stating that AAP is recommended, within its marketing authorisation, as an option for treating mCRPC. ..
  5. Ramaekers B, Wolff R, Pouwels X, Oosterhoff M, van Giessen A, Worthy G, et al. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018;: pubmed publisher
    ..The committee concluded that the incremental cost-effectiveness ratio was within the range that could be considered a cost-effective use of National Health Service resources. ..
  6. Ramaekers B, Wolff R, van Giessen A, Pouwels X, Fayter D, Lang S, et al. Trifluridine-Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018;36:285-288 pubmed publisher
    ..Since the AC concluded that the most plausible ICER was £49,392 per QALY gained, and that T/T meets end-of-life criteria, T/T was recommended as a cost effective use of NHS resources. ..

Detail Information

Publications6